Literature DB >> 12794577

Factors affecting cost and length of stay associated with the ileal pouch-anal anastomosis.

Brian R Swenson1, Christopher S Hollenbeak, Walter A Koltun.   

Abstract

PURPOSE: The purpose of this study was to evaluate the costs associated with the ileal pouch-anal anastomosis procedure and identify those factors that most affected or determined such costs. Specifically evaluated were the costs, complication rates, and length of stay associated with the ileal pouch-anal anastomosis done as a one-stage, two-stage, two-stage modified, or three-stage procedure.
METHODS: Costs from the hospital accounting database and clinical data from retrospective chart review of 135 ileal pouch-anal anastomosis patients from a ten-year period were compiled. Overall costs and length of stay (the sum of all hospitalizations for all surgeries and any related complications) for each group were compared by analysis of variance. Linear regression was used to compute net costs and length of stay excluding contributions from other relevant factors such as number of operative stages, complications, demographics, and nonelective operations.
RESULTS: The average overall cost and length of stay of the ileal pouch-anal anastomosis ranged from a low of $12,738 and 13.5 days for the one-stage procedure to a high of $32,758 and 23.9 days for the three-stage pathway. Overall costs, length of stay, and incidence of complications increased with the number of operations necessary to complete the ileal pouch-anal anastomosis. This pattern of increased costs and length of stay with the greater number of stages persisted even after demographic and preoperative characteristics were controlled for in the analyses. The occurrence of a complication added an average of $9,304 (P < 0.0001) and 7.4 days to the procedure (P = 0.0002), whereas an urgent presentation added an average of $5,258 (P = 0.15) and 6.1 days (P = 0.04).
CONCLUSIONS: The two most definitive determinants of cost and length of stay after ileal pouch-anal anastomosis are complications and number of operative stages used to complete the operation. Elective ileal pouch-anal anastomosis operations done in the fewest stages with the least complications provide the least costly result and the shortest hospital stay. For patients with severe disease, the two-stage modified pathway (total abdominal colectomy followed by pouch creation without a protecting ileostomy) appears to have fewer complications, lower costs, and a shorter length of stay than the traditional three-stage pathway.

Entities:  

Mesh:

Year:  2003        PMID: 12794577     DOI: 10.1007/s10350-004-6653-7

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  7 in total

Review 1.  Modified two-stage restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis: a systematic review and meta-analysis of observational research.

Authors:  William Yu Luo; Siddharth Singh; Raphael Cuomo; Samuel Eisenstein
Journal:  Int J Colorectal Dis       Date:  2020-07-26       Impact factor: 2.571

2.  Surgical management of ulcerative colitis: a comparison of Canadian and American colorectal surgeons.

Authors:  Devon Richardson; Sandra deMontbrun; Paul M Johnson
Journal:  Can J Surg       Date:  2011-08       Impact factor: 2.089

3.  Long-term direct costs before and after proctocolectomy for ulcerative colitis: a population-based study in Olmsted County, Minnesota.

Authors:  Stefan D Holubar; Kirsten Hall Long; Edward V Loftus; Bruce G Wolff; John H Pemberton; Robert R Cima
Journal:  Dis Colon Rectum       Date:  2009-11       Impact factor: 4.585

4.  Which adverse events are associated with mortality and prolonged length of stay following colorectal surgery?

Authors:  Rocco Ricciardi; Patricia L Roberts; Thomas E Read; Jason F Hall; Peter W Marcello; David J Schoetz
Journal:  J Gastrointest Surg       Date:  2013-05-21       Impact factor: 3.452

5.  Fertility Impact of Initial Operation Type for Female Ulcerative Colitis Patients.

Authors:  Adam S Faye; Aaron Oh; Lindsay D Kumble; Ravi P Kiran; Timothy Wen; Garrett Lawlor; Simon Lichtiger; Maria T Abreu; Chin Hur
Journal:  Inflamm Bowel Dis       Date:  2020-08-20       Impact factor: 5.325

6.  Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis.

Authors:  Feng Xie; Gord Blackhouse; Nazila Assasi; Kathryn Gaebel; Diana Robertson; Ron Goeree
Journal:  Cost Eff Resour Alloc       Date:  2009-12-11

7.  Better characterization of operation for ulcerative colitis through the National surgical quality improvement program: A 2-year audit of NSQIP-IBD.

Authors:  William Y Luo; Stefan D Holubar; Liliana Bordeianou; Bard C Cosman; Roxanne Hyke; Edward C Lee; Evangelos Messaris; Julia Saraidaridis; Jeffrey S Scow; Virginia O Shaffer; Radhika Smith; Randolph M Steinhagen; Florin Vaida; Samuel Eisenstein
Journal:  Am J Surg       Date:  2020-06-12       Impact factor: 2.565

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.